Anna Turetsky

Principal, Venture Investments, The Mark Foundation

Anna has been a Principal of Venture Investments at The Mark Foundation for Cancer Research since November 2019. She is on the Board of Verseau Therapeutics, and a Board Observer at Accent Therapeutics, Interius BioTherapeutics, and C2i Genomics, a startup from EFL’s 2019-2020 cohort that initially launched based on grant funding from the Mark Foundation. Prior to the Foundation, Anna was a Vice President at Lightstone Ventures, a global, early-stage venture fund investing in the biopharmaceutical and medical device sectors. She played a major role in the firm’s investments in Tizona Therapeutics (acquired by Gilead), Gemini Therapeutics (NASDAQ: GMTX), Locana, Cyteir Therapeutics, and Disarm Therapeutics (acquired by Eli Lilly), and served as an Observer on the Boards of Directors of these companies. Anna’s additional work experience includes internships and strategic consulting for corporate venture funds and biotech companies. Anna holds a Ph.D. in Biophysics from Harvard University and a BA in Biochemistry from the University of Pennsylvania. At Harvard, Anna completed her graduate research as an NSF Graduate Research Fellow in the Center for Systems Biology at Massachusetts General Hospital.